SCHEMBL5658290

SCHEMBL5658290

COc1cc(C/C(C#N)=C/Nc2ccccc2)c2cc(Cc3ccc(F)cc3)oc2c1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
GPR55 Q9Y2T6 3/20 0.36
CNR2 P34972 3/20 0.36
CNR1 P21554 2/20 0.36
ALDH1A1 P00352 4/20 0.33
KMT2A Q03164 4/20 0.33
HPGD P15428 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 2/20 0.33
POLB P06746 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 3/20 0.32
HTT P42858 2/20 0.32
GAA P10253 2/20 0.32
TP53 P04637 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
FABP4 P15090 1/20 0.31
FABP5 Q01469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658293 1.00 SMN1; SMN2 (0.36) SMN1; SMN2GPR55CNR2CNR1ALDH1A1
SCHEMBL5659089 0.94 KDM4E (0.37) SMN1; SMN2GPR55CNR2CNR1ALDH1A1
SCHEMBL5659091 0.94 KDM4E (0.37) SMN1; SMN2GPR55CNR2CNR1ALDH1A1
SCHEMBL5657744 0.89 HIF1A (0.36) SMN1; SMN2ALDH1A1KMT2AMEN1MAPT
SCHEMBL5657741 0.89 HIF1A (0.36) SMN1; SMN2ALDH1A1KMT2AMEN1MAPT
SCHEMBL5657615 0.84 ALOX5 (0.31) SMN1; SMN2POLB
SCHEMBL5657612 0.84 ALOX5 (0.31) SMN1; SMN2POLB
SCHEMBL5658394 0.83 MEN1 (0.33) SMN1; SMN2ALDH1A1KMT2AHPGDMEN1
SCHEMBL5658396 0.83 MEN1 (0.33) SMN1; SMN2ALDH1A1KMT2AHPGDMEN1
SCHEMBL5657381 0.82 MEN1 (0.32) ALDH1A1KMT2AMEN1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030130-B2 Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2006-04-18 US disclosed
EP-1307445-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2005-12-21 EP disclosed
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents EVOLVA SA (CH) 2004-02-19 US disclosed
EP-1307445-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Arpida AG, (CH) 2003-05-07 EP disclosed
WO-2002010157-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents SBDS, BPTF, DCXR SMN1; SMN2 3686/4885GPR55 3279/4885CNR2 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.